The Broad Institute, Inc.; Inc.;Dana-Farber Cancer Institute, Inc.;The Broad Institute
发明人:
Garraway, Levi A.,Johannessen, Cory M.
申请号：
AU2011224410
公开号：
AU2011224410B2
申请日:
2011.03.09
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.
